Studies have reported that DYRK2 can inhibit tumor cell proliferation via interactions with a variety of tumor suppressor genes, and reduced DYRK2 expression is strongly linked to weak chemotherapeutic efficacy and poor prognosis.224. The gene discussed is DYRK2; the disease is neoplasm.